Skip to main content
OKYO Pharma Ltd logo

OKYO Pharma Ltd — Investor Relations & Filings

Ticker · OKYO ISIN · US6793451088 US Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2025-10-29 Regulatory Filings
Country US United States of America
Listing US OKYO

About OKYO Pharma Ltd

https://okyopharma.com/

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces that the CEO will present at a conference and includes a news announcement as an exhibit. The document is short (2734 characters) and primarily serves as an announcement of an event rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed disclosures typical of annual or quarterly reports. It also does not fit into categories like earnings release, capital update, or legal proceedings. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-10-29 English
6-K
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It reports that Panetta Partners Limited, associated with the Executive Chairman, acquired additional shares, increasing beneficial ownership. The document is short (2835 characters) and primarily serves as an announcement of a shareholding change, referencing an attached news announcement (Exhibit 99.1). There is no detailed financial data or comprehensive report content. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is not a full financial report, earnings release, or regulatory filing of another type, but a specific ownership change disclosure.
2025-10-16 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, OKYO Pharma LTD, with the SEC. It announces a Registration Pathway with a 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain. The document is short (2700 characters) and primarily serves as an announcement of this news, with an exhibit (99.1) referenced as the news announcement. There are no financial statements, detailed financial data, or management discussion present. The document is not an annual or quarterly report, nor is it a certification or voting result. It is a regulatory announcement filed under the Securities Exchange Act of 1934, typical of Form 6-K filings which are used for current reports by foreign private issuers. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full report or other specific category.
2025-09-22 English
20-F/A
Annual Report FY 2025
2025-08-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-05 English
20-F
Annual Report FY 2025
2025-07-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.